---
layout: post
title: "Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments"
date: 2026-02-05 18:55:10 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-07518
original_published: 2023-04-11 00:00:00 +0000
significance: 8.00
---

# Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** April 11, 2023 00:00 UTC
**Document Number:** 2023-07518

## Summary

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The committee will discuss the Biologics License Application (BLA) 125781 from Sarepta Therapeutics, Inc. for delandistrogene moxeparvovec with the requested indication for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/04/11/2023-07518/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establishment-of-a-public)
- API: https://www.federalregister.gov/api/v1/documents/2023-07518

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
